PRTC News and Press, PureTech Health plc From 08/24/22

Strategic partnership created to develop and license a new vocal biomarker detection and monitoring capability for COPD in India PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a biotherapeutics company, today anno...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2022, on Thursday, August 25, 2022. A presentation and conference call for analysts and shareholders will take place at 9:00am ...

Pivotal study follows successful Phase 2 trial, which demonstrated improvements in attention function as compared to both treatment as usual and single task video game groups Pivotal Data Readout expected in 2H2023 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (&...

Data show correlation between targeted activity in the brain and improvement in motor speed and executive function, providing further validation of Akili’s technology platform and its potential to improve select cognitive impairments across different indications Data al...

IPF study will evaluate efficacy of two doses of LYT-100, one with comparable exposure to FDA-approved dose of pirfenidone and one with higher exposure, vs. placebo, as well as relative tolerability and efficacy vs. pirfenidone Bi-monthly, monotherapy dose escalation portion o...

Multi-product CGMP facility designed to meet global regulatory standards for the manufacture of oral therapies based on defined bacterial consortia Facility will supply planned Phase 3 clinical trial and potential commercial launch of VE303 in Clostridioides difficile infe...

LYT-300 achieved systemic blood levels approximately nine-fold greater compared to previous reports with oral allopregnanolone. 1 Allopregnanolone is a neurosteroid with proven efficacy that is currently only approved as a 60-hour intravenous infusion. LYT-300, an orally a...

No treatment effect observed in this patient population; substantial improvement in 6-minute walk test seen in both placebo and active groups Study adds to growing body of data supporting strong safety and tolerability profile of LYT-100 (deupirfenidone) Company wi...

Franklin brings proven track record leading early commercialization and growing disruptive healthcare business models, including at Exact Sciences, Foundation Medicine and Boston Scientific Franklin to oversee Akili’s Commercial, Product, Engineering, Medical and Pe...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that Bharatt Chowrira, Ph.D., J.D....